Welcome to our dedicated page for AVANOS MEDICAL SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AVANOS MEDICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AVANOS MEDICAL's regulatory disclosures and financial reporting.
Franchini Indrani Lall reported acquisition or exercise transactions in this Form 4 filing.
Avanos Medical director Indrani Lall Franchini received a grant of 12,003 restricted share units on May 8, 2026. These units are a cash-settled award, each representing a contingent right to receive a payment equal to the value of one share of Avanos common stock.
The new 12,003 restricted share units replace a prior grant originally issued on January 2, 2025. The units vest when Franchini terminates her service on Avanos Medical’s Board of Directors, aligning the award with her continued board tenure rather than short-term performance.
OLEARY PATRICK J reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Patrick J. O’Leary received a grant of 12,003 restricted share units on May 8, 2026 as compensation. Each unit represents a contingent right to a cash payment equal to the value of one share of Avanos common stock.
These units were issued to replace restricted share units originally granted on January 2, 2025. The award vests when O’Leary’s service on the company’s Board of Directors ends, meaning the units are long-term, service-based compensation rather than an immediate cash payout.
Shimer Julie Ann reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Julie Ann Shimer reported a compensation-related grant of 12,003 restricted share units on May 8, 2026. Each unit is a contingent right to receive a cash payment equal to the value of one share of Avanos common stock.
These restricted share units were issued to replace units originally granted on January 2, 2025, and will vest when Shimer terminates her service on the company’s Board of Directors. Following this award, she holds 12,003 restricted share units directly.
T. Rowe Price Investment Management, Inc. filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership of 1,703,510 shares of Avanos Medical Inc. common stock, representing 3.7% of the class as of 04/30/2026. The filer states it owns 5% or less and disclaims beneficial ownership in the filing.
Avanos Medical Inc. ownership update: T. Rowe Price Investment Management reports beneficial ownership of 5,330,776 shares of Common Stock, representing 11.5% of the class as of 03/31/2026. The filing amends prior disclosures and notes that T. Rowe Price Small-Cap Value Fund holds 2,839,254 shares (6.1%).
Avanos Medical reported first-quarter 2026 results and outlined a pending cash merger that will take the company private. Net sales rose to $182.2 million from $167.5 million, driven mainly by Specialty Nutrition Systems, while net income declined to $5.1 million from $6.6 million, or $0.11 per diluted share.
Specialty Nutrition Systems revenue grew to $124.0 million, including contributions from the 2025 Nexus acquisition, while Pain Management and Recovery was roughly flat at $56.3 million. Operating income was $8.9 million, and adjusted operating income was $16.2 million, reflecting restructuring and acquisition-related costs.
Cash and equivalents were $65.6 million and term loan debt was $98.4 million, with operating activities using $12.3 million of cash in the quarter. A restructuring plan tied to the 2023 Respiratory Health divestiture has generated $43.1 million of cumulative expenses and is expected to run through 2026.
After quarter-end, Avanos agreed to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash, with all shares and equity awards to be cashed out at closing. The transaction requires shareholder approval and regulatory clearances and, if completed, will result in Avanos being delisted from the New York Stock Exchange.
Avanos Medical, Inc. reported first quarter 2026 results and highlighted a pending acquisition by affiliates of American Industrial Partners in an all-cash transaction valuing the company at an enterprise value of $1.272 billion.
For the quarter, net sales were $182.2 million, up 8.8% from $167.5 million a year earlier, driven by double-digit organic growth in the Specialty Nutrition Systems segment. Net income was $5.1 million versus $6.6 million last year, with diluted EPS of $0.11 compared to $0.14. Adjusted net income was $10.6 million and adjusted diluted EPS $0.22, down from $12.0 million and $0.26.
Specialty Nutrition Systems net sales rose to $124.0 million, while Pain Management & Recovery net sales were $56.3 million and roughly flat year over year, with that segment moving to an operating loss of $1.8 million. Adjusted EBITDA was stable at $21.8 million versus $21.6 million.
Cash used in operating activities was $12.3 million, compared with cash provided of $25.7 million in the prior-year quarter. Free cash flow was an outflow of $16.6 million versus an inflow of $19.0 million. Cash and cash equivalents were $65.6 million as of March 31, 2026, with total debt of $98.2 million on the term loan facility.
AVANOS MEDICAL, INC. SVP and Chief Financial Officer Scott Michael Galovan reported a compensation-related share transaction. On April 22, 2026, 4,228 shares of common stock were surrendered to the company to satisfy tax withholding obligations when 12,225 time-based restricted share units vested. This was a tax-withholding disposition rather than an open-market sale. After the transaction, Galovan directly held 135,596 shares of common stock.
Avanos Medical senior vice president of operations Sigfrido Delgado had shares withheld to cover taxes on a stock award. On the vesting of 16,300 time-based restricted share units, 4,264 shares of common stock were surrendered to Avanos Medical to satisfy tax withholding obligations. Each restricted share unit is economically equivalent to one common share. Following this non-market tax-withholding disposition, Delgado directly holds 55,741 shares of Avanos Medical common stock.
AVANOS MEDICAL, INC. Chief Executive Officer David Pacitti reported a routine tax-related share disposition. He surrendered 21,194 shares of Common Stock at $14.53 per share to the company to cover tax withholding due when 72,614 time-based restricted share units vested. After this tax-withholding transaction, he directly holds 322,194 shares of Common Stock.